A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Chavez, Julio C
  • Olszewski, Adam J
  • Bastos-Oreiro, Mariana
  • Assouline, Sarit E
  • Lossos, Izidore S
  • Diefenbach, Catherine
  • Ghosh, Nilanjan
  • Modi, Dipenkumar
  • Sabry, Waleed
  • Naik, Seema
  • Shah, Nirav N
  • Foley, Ronan
  • Hodson, Daniel J
  • Makadia, Sneha
  • Pham, Song
  • Penuel, Elicia
  • Wu, Hao
  • Ead, Wahib S
  • To, Iris
  • Batlevi, Connie Lee
  • Wei, Michael C
  • Budde, L Elizabeth

publication date

  • November 5, 2024

published in